Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease

Laboratory Investigation

Volumn 91, Issue 2, 2011, Pages 283-293

  Alisi, Anna ^a   Da Sacco, Letizia ^a   Bruscalupi, Giovannella ^b   Piemonte, Fiorella ^a   Panera, Nadia ^a   De Vito, Rita ^a   Leoni, Silvia ^b   Bottazzo, Gian Franco ^a   Masotti, Andrea ^a   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

microRNA; NAFLD; steatohepatitis; targets

Indexed keywords

EPHRIN A1; EPHRIN RECEPTOR A2; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C DELTA; PROTEIN LITAF; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIET; GENETIC ANALYSIS; MIRNOME ANALYSIS; MUTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DIET; DIETARY FATS; FATTY LIVER; FRUCTOSE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LIVER; MICROARRAY ANALYSIS; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79551592245     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.166     Document Type: Article

References (61)

1. Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis 2009;13:511-531.
2. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
3. Bondini S, Kleiner DE, Goodman ZD, et al. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:17-23, vii.
4. Paradis V, Bedossa P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes Metab 2008;34: 638-642.
5. Utzschneider KM, Kahn SE. Review: the role of insulin resistance nonalcoholic fatty liver disease. J Clin Endocrin Metab 2006;91:4753-4761.
6. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50: S412-S416.
7. Malaguarnera M, Di Rosa M, Nicoletti F, et al. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009;87:679-695.
8. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009;25:230-237.
9. Alisi A, Marcellini M, Nobili V. Bioinformatics as tool to identify gene/ protein-pathways associated with nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. Hepatology 2007;46:1306.
10. Baranova A, Schlauch K, Elariny H, et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with nonalcoholic fatty liver disease. Obes Surg 2007;17:1111-1118.
11. Baranova A, Liotta L, Petricoin E, et al. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:209-220.
12. Barbato C, Arisi I, Frizzo ME, et al. Computational challenges in miRNA target predictions: to be or not to be a true target? J Biomed Biotechnol 2009;2009:803069.
13. Calvert VS, Collantes R, Elariny H, et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007;6:166-172.
14. Alisi A, Masotti A, Nobili V. Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. Hepatology 2009;49:706-707.
15. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
16. Ambros V. The functions of animal microRNAs. Nature 2004;431: 350-355.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
18. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007;8:215-239.
19. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 2008;7:3655-3660.
20. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet 2004;20:617-624.
21. Karp X, Ambros V. Encountering microRNAs in cell fate signaling. Science 2005;310:1288-1289.
22. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-5856.
23. Pandey AK, Agarwal P, Kaur K, et al. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009;23:221-232.
24. Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol 2009;15:5633-5640.
25. Chen XM. MicroRNA signatures in liver diseases. World J Gastroenterol 2009;15:1665-1672.
26. Li S, Chen X, Zhang H, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009;50:1756-1765.
27. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008;48:1810-1820.
28. Jin X, Ye Y-F, Chen S-H, et al. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 2009;41: 289-297.
29. Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR- 200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010. Epub ahead of print.
30. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241-246.
31. Bolstad BM, Irizarry RA, Astrandand MT, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
33. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129V2141.
34. Alisi A, Spagnuolo S, Leoni S. Treatment with EGF increases the length of S-Phase after partial hepatectomy in rat, changing the activities of cdks. Cell Physiol Biochem 2003;13:239-248.
35. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773.
36. Wang X. Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res 2006;34:1646-1652.
37. Sood P, Krek A, Zavolan M, et al. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci USA 2006;103:2746-2751.
38. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27:44-54.
39. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006;99:671-678.
40. Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev 2009;23: 1313-1326.
41. Vinciguerra M, Sgroi A, Veyrat-Durebex C, et al. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009;49:1176-1184.
42. Ji J, Zhang J, Huang G, et al. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009;583:759-766.
43. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-2207.
44. Yu S, Matsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003;278:49-505.
45. Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol 2008;7:192-199.
46. Watanabe S, Horie Y, Kataoka E, et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 2007;22:S96-S100.
47. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-1346.
48. Peterfy M, Phan J, Xu P, et al. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 2001;27:121-124.
49. Wiedmann S, Fischer M, Koehler M, et al. Genetic variants within the LPIN1 gene, encoding lipin, are influencing phenotypes of the metabolic syndrome in humans. Diabetes 2008;57:209-217.
50. Tang X, Marciano DL, Leeman SE, et al. LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6(B) with effects on multiple cytokines. Proc Natl Acad Sci USA 2005;102: 5132-5137.
51. Alisi A, Panera N, Nobili V. Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease. Hepatology 2010;51:714-715.
52. Copple BL, Bustamante JJ, Welch TP, et al. Hypoxia-inducible factordependent production of profibrotic mediators by hypoxic hepatocytes. Liver Int 2009;29:1010-1021.
53. Scharte M, Han X, Uchiyama T, et al. LPS increases hepatic HIF-1alpha protein and expression of the HIF-1-dependent gene aldolase A in rats. J Surg Res 2006;135:262-267.
54. Castaldo G, Calcagno G, Sibillo R, et al. Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin Chem 2000;46:901-906.
55. Ivanov AI, Romanovsky AA. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 2006;58:389-394.
56. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008;6:1795-1806.
57. Kushiyama A, Shojima N, Ogihara T, et al. Resistin-like molecule beta activates M.A.PKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem 2005;280:42016-42025.
58. Redaelli CA, Semela D, Carrick FE, et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004;40:305-312.
59. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by miRNAs: are the answers in sight? Nat Rev Genet 2008;9:102-114.
60. Pillai RS. MiRNA function: multiple mechanisms for a tiny RNA? RNA 2005;11:1753-1761.
61. Masotti A, Da Sacco L, Bottazzo GF, et al. Microarray technology: a promising tool in the field of nutrigenomics discoveries. Crit Rev Food Sci Nutr 2010;50:693-698.